Two years after Gilead secured the…
Two years after Gilead secured the first option on Assembly [...]
Boehringer Ingelheim has opened…
Boehringer Ingelheim has opened another front in its attack on [...]
Big Pharma-backed Aktis Oncology…
Big Pharma-backed Aktis Oncology has announced plans to go public [...]
Having kicked off the year with a…
Having kicked off the year with a $200 million series [...]
Ipsen may be a recent entrant into…
Ipsen may be a recent entrant into the antibody-drug conjugate [...]
Ipsen’s oral small molecule…
Ipsen’s oral small molecule failed to reduce the progression of [...]
Venture capital firm Aditum Bio is…
Venture capital firm Aditum Bio is going all-out for a [...]
Merck & Co. is turning down…
Merck & Co. is turning down its option to license [...]
Altimmune has shared an update on…
Altimmune has shared an update on the metabolic dysfunction-associated steatohepatitis [...]
Boehringer Ingelheim has turned…
Boehringer Ingelheim has turned down its chance to license Nxera [...]